Clinical trial · Observational
Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
A Non-interventional, Observational Qualitative Interview Study of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
NCT07008963CI-TRIAL-00103874completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| non-interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Patient attitude and experience reported by patients regarding capivasertib dosing schedule and regimen
- timeFrame
- Day 1
- description
- The interview will be conducted using a discussion guide tailored to specific questions to be explored in this study, developed by the study team. No formal scale or validated questionnaire will be used to assess the outcomes
Secondary outcomes (1)
- measure
- Self-reported tolerability experiences related to patients' ability to follow the prescribed regimen and stay on treatment among those who received capivasertib + fulvestrant.
- timeFrame
- Day 1
- description
- The interview will be conducted using a discussion guide tailored to specific questions to be explored in this study, developed by the study team. No formal scale or validated questionnaire will be used to assess the outcomes
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria (self-reported): * Adult (over the age of 18 years) * Diagnosed with HR+/HER2- metastatic breast cancer * Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation) Exclusion criteria (self-reported): * Patients who had discontinued capivasertib for more than 6 months before the date of the interview * Unable or unwilling to follow study procedures (including providing informed consent) * Not proficient in spoken English, as assessed by the moderator * Receiving capivasertib in a clinical trial setting * Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)
References
Publications (0)
Data not yet available
No reference posted for this study.